Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock

Pietro Martinoia
Tagged:

Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering.Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public offering…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Pietro Martinoia

…

This content is for Standard 1 Year members only.
Login Join Now